N/A N=302 Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia
Dementia
Primary: Quality of Communication and Decision-making — 6.0; 5.6; 3.7; 3.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002
Phase 3 N=1,025 Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Change From Baseline in HbA1c 26 Weeks After Randomisation — -0.12; 0.005; -0.09 percentage of HbA1c — p=<0.001
Phase 2 N=110 Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection
Adult Primary Liver Cancer · Hepatitis C Infection
Primary: Change in Serum AFP Levels — -1.928; 5.855 ng/mL — p=0.160
Phase 2 N=64 A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children
Hematologic Diseases · Neoplasms
Primary: Dose of Remifentanil Required to Prevent Movement in Response to Lumbar Puncture Needle Insertion — 0.96; 0.28; 1.50; 0.52 micrograms/kg
N/A N=19 Frequency of Denture Cleanser Use and Denture Cleanliness
Denture Cleansers
Primary: Change From Baseline in Aerobic Bacteria Microbial Count on Day 7 — -1.78; -1.20 log10(CFU[colony forming unit]/disc+1) — p=0.0144
N/A N=135 Assessment of the Efficacy of an Experimental Occlusion Technology Dentifrice in Dentinal Hypersensitivity
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score at Week 8 — -0.94; -0.33 score on a scale — p=<.0001
Phase 3 N=1,463 Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX — 2130 TEAEs
Phase 2 N=29 Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Recurrent Salivary Gland Cancer · Stage IVA Salivary Gland Cancer · Stage IVB Salivary Gland Cancer
Primary: Response Rate — 1; 2; 23; 3 Participants
N/A N=24 TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended
Diabetic Foot Ulcers
Primary: Changes in Signs and Symptoms of Local Infection — 2; 1; 0 Participants
N/A N=148 Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa
Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Proportion of Waking Day Spent in "Off") Score: Mean Change From Baseline to the…
Phase 3 N=29 Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Primary: Number of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab — 12; 8; 8; 4 Participants
Phase 2 N=109 Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF) — -23.3; -74.0 percent change
Phase 3 N=251 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
Turner Syndrome · Renal Insufficiency, Chronic · Pituitary Diseases
Primary: Insulin-Like Growth Factor I (IGF-I) Levels Measured Using the Timed Capillary Blood Spot Samples — 223.54; 212.97; 238.02; 226.90 nanograms/milliliter (ng/mL)
Phase 3 N=173 Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)
Saphenous Vein Graft Disease
Primary: Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year — 14; 16 Vein grafts